Clinical and Laboratory Improvement in Hyperadrenergic Postural Orthostatic Tachycardia Syndrome (POTS) after COVID-19 Infection
暂无分享,去创建一个
[1] P. Taub,et al. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. , 2021, Journal of the American College of Cardiology.
[2] P. Brodin. Immune determinants of COVID-19 disease presentation and severity , 2021, Nature Medicine.
[3] R. Sutton,et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. , 2020, Clinical medicine (London).
[4] B. Grubb,et al. New-onset Postural Orthostatic Tachycardia Syndrome Following Coronavirus Disease 2019 Infection , 2020, The Journal of innovations in cardiac rhythm management.
[5] A. Tanuri,et al. Current evidence of neurological features, diagnosis, and neuropathogenesis associated with COVID-19 , 2020, Revista da Sociedade Brasileira de Medicina Tropical.
[6] K. Nugent,et al. Dysautonomia: An Overlooked Neurological Manifestation in a Critically ill COVID-19 Patient , 2020, The American Journal of the Medical Sciences.
[7] C. Stecco,et al. Sympathetic activation: a potential link between comorbidities and COVID‐19 , 2020, The FEBS journal.
[8] B. Levine,et al. Postural Orthostatic Tachycardia Syndrome: JACC Focus Seminar. , 2019, Journal of the American College of Cardiology.
[9] P. Taub,et al. Postural Orthostatic Tachycardia Syndrome: Prevalence, Pathophysiology, and Management , 2018, Drugs.
[10] A. Abdulla,et al. Reversible postural orthostatic tachycardia syndrome. , 2015, World journal of clinical cases.
[11] U. Graham,et al. Postural orthostatic tachycardia syndrome , 2009, BMJ Case Reports.